Nome

Nome (Nome Bio) is a biotechnology platform company dedicated to accelerating the development of personalized therapies for rare genetic diseases. Founded by Steven Ringel, who was diagnosed with an ultra-rare KIZ gene mutation, the company aims to provide an "operating system" for custom drug development, bridging the gap for patients whose conditions are too rare for traditional pharmaceutical interest. Nome leverages AI to evaluate genetic data and coordinates a network of researchers, manufacturers, and regulators to move treatments from concept to clinic. By streamlining the complex drug development process, Nome empowers patients and families to pursue life-saving treatments through pathways like the FDA's Expanded Access. The company's lead pilot program focuses on a gene therapy for KIZ-related vision loss, while its platform supports a growing number of programs across various rare indications.